Henry Schein, Inc.
HealthcareNASDAQ:HSIC · NASDAQ Global Select
+$1.03 today
Vol 1.08M · Avg 1.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$13.4B of revenue converted into $395.0M of net income for the selected period. Gross margin is 29.7% and net margin is 2.9%, showing how much revenue survives after costs and taxes. EPS is $3.31, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2B +4.0% | $12.7B +2.7% | $12.3B -2.4% | $12.6B +2.0% | $12.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.3B +4.9% | $8.9B +2.5% | $8.7B -3.4% | $9.0B +3.1% | $8.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $3.8B +2.0% | $3.8B +3.1% | $3.7B +0.1% | $3.6B -0.6% | $3.7B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 29.1% -0.6pp | 29.7% +0.1pp | 29.6% +0.7pp | 28.9% -0.8pp | 29.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.1B +1.6% | $3.0B +3.4% | $2.9B +8.3% | $2.7B -3.8% | $2.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.1B +1.6% | $3.0B +3.4% | $2.9B +8.3% | $2.7B -3.8% | $2.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $311.0M +4.7% | $297.0M +19.8% | $248.0M +17.0% | $212.0M +1.2% | $209.5M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.0B +6.9% | $941.0M +7.3% | $877.0M -10.2% | $977.0M -8.5% | $1.1B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 7.6% +0.2pp | 7.4% +0.3pp | 7.1% -0.6pp | 7.7% -0.9pp | 8.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $758.0M +4.0% | $729.0M +2.1% | $714.0M -23.9% | $938.0M +9.7% | $854.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 5.7% -0.0pp | 5.8% -0.0pp | 5.8% -1.6pp | 7.4% +0.5pp | 6.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $33.0M +37.5% | $24.0M +41.2% | $17.0M +0.0% | $17.0M +163.5% | $6.5M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $150.0M +14.5% | $131.0M +50.6% | $87.0M +97.7% | $44.0M +59.4% | $27.6M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$213.0M -4.9% | -$203.0M -28.5% | -$158.0M +21.8% | -$202.0M -4651.8% | -$4.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $545.0M +3.6% | $526.0M -5.4% | $556.0M -24.5% | $736.0M -13.5% | $850.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 4.1% -0.0pp | 4.2% -0.4pp | 4.5% -1.3pp | 5.8% -1.0pp | 6.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $126.0M -1.6% | $128.0M +6.7% | $120.0M -29.4% | $170.0M -13.9% | $197.3M | $1.3B | -$1.6B | $745.2M |
| Net Income | $398.0M +2.1% | $390.0M -6.3% | $416.0M -22.7% | $538.0M -13.8% | $623.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | 3.0% -0.1pp | 3.1% -0.3pp | 3.4% -0.9pp | 4.3% -0.8pp | 5.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +7.2% | $3 -3.5% | $3 -19.5% | $4 -12.4% | $5 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +7.2% | $3 -3.5% | $3 -19.2% | $4 -12.1% | $4 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $120.8M -4.7% | $126.8M -2.9% | $130.6M -4.0% | $136.1M -2.9% | $140.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $121.7M -4.7% | $127.8M -3.0% | $131.7M -4.4% | $137.8M -2.8% | $141.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
Globus Medical, Inc.
NYSE:GMED
$10.84B
Molina Healthcare, Inc.
NYSE:MOH
$10.43B
Masimo Corporation
NASDAQ:MASI
$9.42B
Halozyme Therapeutics, Inc.
NASDAQ:HALO
$8.24B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.73B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Grifols, S.A.
NASDAQ:GRFS
$6.46B
Avantor, Inc.
NYSE:AVTR
$6.41B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HSIC generate?
Henry Schein, Inc. (HSIC) reported $13.18B of revenue in fiscal 2025.
Is HSIC profitable?
Henry Schein, Inc. (HSIC) reported $398.00M of net income, with a net margin of 3.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.